• Erdal Dogan, Mehmet Salim Akdemir, Abdulmenap Guzel, Mehmet Besir Yildirim, Zeynep Baysal Yildirim, Mahir Kuyumcu, Abdurrahman Gümüş, and Hakan Akelma.
• Department of Anesthesiology and Reanimation, Faculty of Medicine, Dicle University Medical School, Diyarbakir, Turkey.
• Biomed Res Int. 2014 Jan 1;2014:945310.

BackgroundSugammadex offers a good alternative to the conventional decurarisation process currently performed with cholinesterase inhibitors. Sugammadex, which was developed specifically for the aminosteroid-structured rocuronium and vecuronium neuromuscular blockers, is a modified cyclodextrin made up of 8 glucose monomers arranged in a cylindrical shape.MethodsIn this study, the goal was to investigate the efficacy of sugammadex. Sugammadex was used when there was insufficient decurarisation following neostigmine. This study was performed on 14 patients who experienced insufficient decurarisation (TOF <0.9) with neostigmine after general anaesthesia in the operating rooms of a university and a state hospital between June, 2012, and January, 2014. A dose of 2 mg/kg of sugammadex was administered.ResultsTime elapsed until sugammadex administration following neostigmine 37 ± 6 min, following sugammadex it took 2.1 ± 0.9 min to reach TOF ≥0.9, and the extubation time was 3.2 ± 1.4 min. No statistically significant differences were detected in the hemodynamic parameters before and after sugammadex application. From the time of administration of sugammadex to the second postoperative hour, no side effects or complications occurred. None of the patients experienced acute respiratory failure or residual block during this time period.ConclusionSugammadex was successfully used to reverse rocuronium-induced neuromuscular block in patients where neostigmine was insufficient.

16 keywords...

hide…